Targeted Protein degradation is being explored as a substitute strategy in cancer, whereby the purely natural protein degradation technique is co-opted for therapeutic applications. Not too long ago formulated novel molecules termed proteolysis-focusing on chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. Just one ligand binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/